Document is current
Any future updates will be listed below
-
Authors
Schmidt, Ralf
Nguyen, Thanh
Bicu, Alicia S.
Cvachovec, Paula
Siefert, Victor
Eckl, Miriam
Willam, Marvin
Froelich, Matthias F.
Schoenberg, Stefan O.
Ehmann, Michael
Buergy, Daniel
Clausen, Sven
Fleckenstein, Jens
Giordano, Frank A.
Boda-Heggemann, Judit
Dreher, Constantin
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Mannheim der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 24 June 2025
Accepted: 17 September 2025
First Online: 16 October 2025
Declarations
:
: This observational study is IRB-approved (Ref:2023 − 557) at the Medical Faculty Mannheim, University of Heidelberg.
: Not applicable.
: C.D. reports Varian research grant and travel expenses, AstraZeneca speaker fees and travel expenses, and DGVS speaker fees and travel expenses. D.B. reports NB Capital ApS (Consultation, personal fees), PharmaMar GmbH (speaker) and AstraZeneca GmbH (speaker).J.B-H. reports AstraZeneca speaker fees and consulting honoraria EbaMed SA.F.A.G. reports travel expenses, stocks and honoraria from TME Pharma AG; research grants and travel expenses from ELEKTA AB; grants, research grants, travel expenses and honoraria from Carl Zeiss Meditec AG; grants, research grants, travel expenses and honoraria from OncoMANGETx, Inc.; travel expenses and research grants from Varian Medical Systems, Inc.; travel expenses and/or honoraria from Bristol- Myers Squibb, Cureteq AG, Roche Pharma AG, MSD Sharp and Dohme GmbH, Siemens Healthineers AG, Varian Medical Systems, and AstraZeneca GmbH; non-financial support from Oncare GmbH and Opasca GmbH and patent US10857388B2 together with Carl Zeiss Meditec AG and patent EP4119191A1.
